With concurrent activation, such as Polyinosinic:polycytidylic acid (poly I:C) and anti-CD40, the administered tumor antigen-receptor complex was shown to elicit effective immune responses and inhibit tumor growth. The gene discussed is CD40; the disease is neoplasm.